3-Methyl-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-imidazolidinedione | 852391-16-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-Methyl-5-[(7-methyl-1H-indol-3-yl)methyl]-2,4-imidazolidinedione
• 英文别名: 3-methyl-5-[(7-methyl-1H-indol-3-yl)methyl]imidazolidine-2,4-dione
• CAS: 852391-16-3
• 化学式: C₁₄H₁₅N₃O₂
• 分子量: 257.29
• InChiKey: BVGLUUAWBVHTFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  65.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• IDENTIFICATION AND TREATMENT OF VULNERABLE PLAQUES
  申请人：OTTAWA HEART INSTITUTE RESEARCH CORPORATION

  公开号：US20160324992A1

  公开（公告）日：2016-11-10

  A method of detecting an atherosclerotic plaque vulnerable to rupture in a subject comprises providing to the subject a labelled necrostatin or a derivative thereof, and visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture. A method of detecting and treating an atherosclerotic plaque vulnerable to rupture comprises providing to the subject a labelled necrostatin or a derivative thereof, visualizing the label, wherein a localization of the label in a plaque indicates the plaque is vulnerable to rupture; and providing a necroptosis inhibitor or derivative thereof to the subject when the visualizing indicates that the plaque is vulnerable to rupture. The necroptosis inhibitor may comprise a necrostatin, such as Nec-1. The label may be a radiolabel such as 123 I. By visualizing plaques vulnerable to rupture, atherosclerotic plaques may be identified and treated in advance of rupture.

  在一个主体中检测易破裂的动脉粥样硬化斑块的方法包括向主体提供标记的坏死激酶抑制剂或其衍生物，并可视化标记，标记在斑块中的定位表明该斑块易破裂。检测和治疗易破裂的动脉粥样硬化斑块的方法包括向主体提供标记的坏死激酶抑制剂或其衍生物，可视化标记，标记在斑块中的定位表明该斑块易破裂；当可视化表明斑块易破裂时，向主体提供坏死激酶抑制剂或其衍生物。坏死激酶抑制剂可能包括坏死激酶，如Nec-1。标记可以是放射性标记，如123I。通过可视化易破裂的斑块，可以提前识别和治疗动脉粥样硬化斑块。
• Inhibitors of cellular necrosis
  申请人：Cuny Gregory D.

  公开号：US20110144169A1

  公开（公告）日：2011-06-16

  The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.

  本发明涉及化合物及其制药制剂，以及它们在治疗预防或治疗创伤、缺血、中风和与细胞死亡相关的退行性疾病中的应用。本发明的方法和组合物特别适用于治疗与细胞坏死相关的神经系统疾病。
• INHIBITORS OF CELLULAR NECROSIS
  申请人：Cuny Gregory D.

  公开号：US20120149702A1

  公开（公告）日：2012-06-14

  The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.

  本发明涉及化合物和药物制剂及其在预防或治疗与细胞死亡相关的创伤、缺血、中风和退行性疾病中的应用。本发明的方法和组合物特别适用于治疗与细胞坏死相关的神经系统疾病。
• Treating male senescence
  申请人：National Institute of Biological Sciences, Beijing

  公开号：US11090307B2

  公开（公告）日：2021-08-17

  The invention provides methods of treating male reproductive senescence comprising administering to a male in need thereof a necroptosis inhibitor, including inhibitors of RIP1, RIP3 or MLKL. The invention also provides pharmaceutical compositions comprising a necroptosis inhibitor and a second different drug for treating male senescence.

  本发明提供了治疗男性生殖衰老的方法，包括向有需要的男性施用坏死抑制剂，包括RIP1、RIP3或MLKL的抑制剂。本发明还提供了包含坏死抑制剂和用于治疗男性衰老的第二种不同药物的药物组合物。
• Hydantoin derivatives as inhibitors of cellular necrosis
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：EP2384753B1

  公开（公告）日：2016-01-06